Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts give Silence Therapeutics a “Moderate Buy” consensus: Of six analysts, four rate the stock a buy, one a strong buy and one a sell. The average 12-month price target is $53.50.
• SLN shares opened at $13.42, with a 52-week range of $4.19 to $17.58 and an approximately $808 million market capitalization. The company’s latest quarterly loss of $0.26 per share was wider than the expected $0.14 loss.
• Institutional ownership is high at 98.73%. Several investors increased or initiated positions, including Bank of America, which raised its stake by 903.8%, and 5AM Venture Management, which purchased a position worth about $5.2 million.

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $53.50.

SLN has been the topic of a number of research analyst reports. Cantor Fitzgerald assumed coverage on Silence Therapeutics in a report on Wednesday, June 24th. They issued an "overweight" rating on the stock. HC Wainwright reiterated a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Wednesday, June 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, Morgan Stanley upped their target price on shares of Silence Therapeutics from $25.00 to $32.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 11th.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $13.42 on Monday. The stock has a fifty day simple moving average of $11.49 and a two-hundred day simple moving average of $8.11. The firm has a market capitalization of $808.02 million, a PE ratio of -10.48 and a beta of 1.39. Silence Therapeutics has a 52-week low of $4.19 and a 52-week high of $17.58.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. On average, sell-side analysts forecast that Silence Therapeutics will post -1.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

Large investors have recently made changes to their positions in the company. AXQ Capital LP purchased a new stake in shares of Silence Therapeutics in the second quarter worth about $138,000. 5AM Venture Management LLC bought a new position in Silence Therapeutics during the second quarter valued at approximately $5,228,676. GAMMA Investing LLC grew its holdings in Silence Therapeutics by 18.1% during the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company's stock valued at $121,000 after buying an additional 1,698 shares in the last quarter. Seven Fleet Capital Management LP increased its stake in Silence Therapeutics by 6.2% in the 1st quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company's stock worth $826,000 after acquiring an additional 9,159 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Silence Therapeutics by 903.8% in the 1st quarter. Bank of America Corp DE now owns 29,773 shares of the company's stock worth $157,000 after acquiring an additional 26,807 shares during the last quarter. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source